Report Information More information from: https://www.wiseguyreports.com/reports/2258248
Tinnitus - Pipeline Review, H2 2017 Report / Search Code: WGR2258248
Price
Description:
1-user PDF : $ 2000.0
Publish Date: 12 September, 2017
Site PDF : $ 4000.0
Enterprise PDF : $ 6000.0
Tinnitus - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus Pipeline Review, H2 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape. Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders). - The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose
Throat Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Contents:
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tinnitus - Overview Tinnitus - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Tinnitus - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tinnitus - Companies Involved in Therapeutics Development AudioCure Pharma GmbH Auris Medical Holding AG Knopp Biosciences LLC Merz Pharma GmbH & Co KgaA Otonomy Inc Pragma Therapeutics SAS SciFluor Life Sciences LLC Sound Pharmaceuticals Inc Tinnitus - Drug Profiles AC-102 - Drug Profile Product Description Mechanism Of Action R&D Progress AM-102 - Drug Profile Product Description Mechanism Of Action R&D Progress AUT-3 - Drug Profile Product Description Mechanism Of Action R&D Progress D-Methionine - Drug Profile Product Description Mechanism Of Action R&D Progress ebselen - Drug Profile Product Description Mechanism Of Action R&D Progress esketamine hydrochloride - Drug Profile
Product Description Mechanism Of Action R&D Progress gacyclidine SR - Drug Profile Product Description Mechanism Of Action R&D Progress GW-1 - Drug Profile Product Description Mechanism Of Action R&D Progress GW-2 - Drug Profile Product Description Mechanism Of Action R&D Progress neramexane mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress RL-81 - Drug Profile Product Description Mechanism Of Action R&D Progress SF-0034 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate KCNQ for Tinnitus - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Kv7.2 for Encephalopathy, Epilepsy, Neuropathic Pain and Tinnitus Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate Neurotrophic Factor for Tinnitus - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile Product Description Mechanism Of Action R&D Progress tetrandrine - Drug Profile Product Description Mechanism Of Action R&D Progress Tinnitus - Dormant Projects Tinnitus - Product Development Milestones Featured News & Press Releases May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of
Acute Inner Ear Tinnitus Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Tinnitus, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Tinnitus - Pipeline by AudioCure Pharma GmbH, H2 2017 Tinnitus - Pipeline by Auris Medical Holding AG, H2 2017 Tinnitus - Pipeline by Knopp Biosciences LLC, H2 2017 Tinnitus - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 Tinnitus - Pipeline by Otonomy Inc, H2 2017 Tinnitus - Pipeline by Pragma Therapeutics SAS, H2 2017 Tinnitus - Pipeline by SciFluor Life Sciences LLC, H2 2017 Tinnitus - Pipeline by Sound Pharmaceuticals Inc, H2 2017 Tinnitus - Dormant Projects, H2 2017 List of Figures Number of Products under Development for Tinnitus, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
wiseguyreports.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349